TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38130645

Group type: EXPERIMENTAL
Intervention: QL0911 (1 μg/kg subcutaneously once weekly for 24 weeks, adjusted to maintain platelet counts from 50 × 10^9/L to 200 × 10^9/L)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo (subcutaneously once weekly for 24 weeks)
Number of subjects: 216
Study: 38130799

Group type: EXPERIMENTAL
Intervention: Digital SPA (digital intervention for pediatric chronic pain)
Number of subjects: 0
Study: 38130916

Group type: COMPARATOR
Intervention: Mepolizumab
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scales (VAS)
Number of subjects: 105
Study: 38131034

Group type: EXPERIMENTAL
Intervention: Sleep duration of 8 hours per day
Number of subjects: 2689

Group type: EXPERIMENTAL
Intervention: Long sleep duration (>8 hours per day)
Number of subjects: 2689

Group type: EXPERIMENTAL
Intervention: Hemoglobin
Number of subjects: 2689

Group type: EXPERIMENTAL
Intervention: Blood urea nitrogen (BUN)
Number of subjects: 2689

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (HDL-c)
Number of subjects: 2689
Study: 38131181

Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavior therapy (Exp-CBT)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Traditional cognitive behavior therapy (T-CBT)
Number of subjects: 274
Study: 38131294

Group type: EXPERIMENTAL
Intervention: Neoadjuvant stereotactic body radiotherapy (SBRT) plus adebrelimab and chemotherapy
Number of subjects: 13
Study: 38131617

Group type: EXPERIMENTAL
Intervention: Tofacitinib maintenance therapy
Number of subjects: 103
Study: 38131621

Group type: EXPERIMENTAL
Intervention: famciclovir 500 mg twice daily for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: natalizumab treatment (before famciclovir)
Number of subjects: 30
Study: 38131628

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (including systemic therapy or chemoradiation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study: 38133080

Group type: EXPERIMENTAL
Intervention: Tongue electrical impedance myography (EIM)
Number of subjects: 4
Study: 38133155

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg plus standard of care for up to 14 days
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 500
Study: 38133156

Group type: EXPERIMENTAL
Intervention: Telemedicine support (telerounds from Monday to Friday, specialists available, continuing education activities)
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Telemedicine support
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Usual care in pediatric intensive care unit
Number of subjects: 1600
Study: 38133554

Group type: EXPERIMENTAL
Intervention: Oral selgantolimod 1.5 mg once weekly for 24 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oral selgantolimod (3 mg or 1.5 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oral selgantolimod (up to 3 mg)
Number of subjects: 48
Study: 38133600

Group type: EXPERIMENTAL
Intervention: PrEPTECH (telehealth intervention)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control (access to an online listing of PrEP resources)
Number of subjects: 229
Study: 38133601

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAA) related HCV cure
Number of subjects: 9735

Group type: COMPARATOR
Intervention: Unhealthy alcohol use
Number of subjects: 9735
Study: 38133639

Group type: EXPERIMENTAL
Intervention: RSVPreF3 60 µg coadministered with dTpa
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: RSVPreF3 120 µg coadministered with dTpa
Number of subjects: 5

Group type: COMPARATOR
Intervention: dTpa coadministered with placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: RSVPreF3 120 µg (second vaccination)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: RSVPreF3 (both doses)
Number of subjects: 5
Study: 38133806

Group type: EXPERIMENTAL
Intervention: mCLIP Partial Prosthesis
Number of subjects: 72
Study: 38133825

Group type: EXPERIMENTAL
Intervention: Malnutrition diagnosed using GLIM criteria at 7 weeks after treatment initiation
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: High scores for nutrition impact symptoms (NIS) assessed by the Head and Neck Patient Symptom Checklist
Number of subjects: 238
Study: 38133914

Group type: EXPERIMENTAL
Intervention: Once-daily sublingual 17-β estradiol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Twice-daily sublingual 17-β estradiol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transdermal 17-β estradiol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Spironolactone (as antiandrogen)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lipid panel, homeostatic model assessment for insulin resistance, coagulation factors II, IX, and XI, Von Willebrand factor, activated protein C resistance, protein C, and protein S
Number of subjects: 100
Study: 38133925

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 16
Study: 38134037

Group type: EXPERIMENTAL
Intervention: automated directly observed therapy-conditional economic incentive (aDOT-CEI) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: aDOT-CEI intervention
Number of subjects: 0
Study: 38134126

Group type: EXPERIMENTAL
Intervention: Live with Wearable Monitoring Device program from trained community health workers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wearable monitoring device only
Number of subjects: 0
Study: 38134136

Group type: EXPERIMENTAL
Intervention: Bilateral active transauricular nerve stimulation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham transauricular nerve stimulation
Number of subjects: 36
Study: 38134231

Group type: EXPERIMENTAL
Intervention: Flortaucipir PET measures in former football players (PRO+COL)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Flortaucipir PET measures in former players over 60 years old
Number of subjects: 218

Group type: COMPARATOR
Intervention: Flortaucipir PET measures for TES groups
Number of subjects: 218
Study: 38134254

Group type: COMPARATOR
Intervention: Step Activity Monitoring (SAM)
Number of subjects: 250

Group type: COMPARATOR
Intervention: High-Intensity Walking (FAST)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Combined Intervention (FAST+SAM)
Number of subjects: 250
Study: 38134265

Group type: EXPERIMENTAL
Intervention: QSM (Quantitative Susceptibility Mapping)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: DCEQP (Dynamic Contrast-Enhanced Quantitative Perfusion)
Number of subjects: 143
Study: 38134260

Group type: EXPERIMENTAL
Intervention: Asymptomatic COVID-19 (AS-COVID)
Number of subjects: 15124

Group type: EXPERIMENTAL
Intervention: Symptomatic COVID-19 (S-COVID)
Number of subjects: 15124

Group type: COMPARATOR
Intervention: COVID-negative controls
Number of subjects: 15124
Study: 38134268

Group type: EXPERIMENTAL
Intervention: Cerebral cavernous malformation patients with symptomatic hemorrhage (SH)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Baseline modified Rankin Scale score of 1
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Baseline National Institutes of Health Stroke Scale score of 0 to 4
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Functional outcomes and patient-reported outcomes
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Score changes as a marker for hemorrhage
Number of subjects: 123
Study: 38134305

Group type: EXPERIMENTAL
Intervention: Monitoring trachoma transmission with antibody data; estimated median IgG half-life of 3 years; seroreversion rate of 2.5 per 100 person-years (95% CI, 1.6-3.5)
Number of subjects: 0
Study: 38134484

Group type: EXPERIMENTAL
Intervention: Femoral nerve block with 100 mg of ropivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sciatic nerve block with 100 mg of ropivacaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sciatic nerve block
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Femoral nerve block and Sciatic nerve block
Number of subjects: 50
Study: 38134562

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Vector-based vaccination
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: mRNA-based vaccination
Number of subjects: 572
Study: 38134936

Group type: EXPERIMENTAL
Intervention: GD2 CAR-Ts (GD2-CAR.OX40.28.z.iC9)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Good expanders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poor expanders
Number of subjects: 0
Study: 38134948

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus cisplatin-based chemotherapy
Number of subjects: 804

Group type: COMPARATOR
Intervention: Placebo plus cisplatin-based chemotherapy
Number of subjects: 804
Study: 38135005

Group type: EXPERIMENTAL
Intervention: MED-mushroom diet (1 serving/d of whole Agaricus bisporus and Pleurotus ostreatus mushrooms)
Number of subjects: 60

Group type: COMPARATOR
Intervention: MED-control diet (without mushrooms)
Number of subjects: 60

Group type: COMPARATOR
Intervention: MED diet (independent of mushroom consumption)
Number of subjects: 60
Study: 38135059

Group type: EXPERIMENTAL
Intervention: Tumor necrosis assessment at baseline
Number of subjects: 294
Study: 38135173

Group type: EXPERIMENTAL
Intervention: PACIFIC ontology for data management
Number of subjects: 0
Study: 38135184

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel + cisplatin + capecitabine as induction chemotherapy for three cycles
Number of subjects: 19
Study: 38135187

Group type: EXPERIMENTAL
Intervention: SMART (Stereotactic MR-guided adaptive radiation therapy) delivered on a 0.35 T MR-guided system prescribed to 50 Gy in 5 fractions
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: SMART (Stereotactic MR-guided adaptive radiation therapy)
Number of subjects: 136
Study: 38135302

Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaboratives (QIC)
Number of subjects: 0
Study: 38135308

Group type: EXPERIMENTAL
Intervention: Psychological distress (caseness on HSCL-10 and PCL-5)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Previous symptoms of depression, fear of infection, and feeling of loneliness
Number of subjects: 287
Study: 38135314

Group type: EXPERIMENTAL
Intervention: Molecular search for TB in stool samples with Xpert assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of pulmonary TB signs on chest X-rays with CAD4TB technology
Number of subjects: 0
Study: 38135320

Group type: EXPERIMENTAL
Intervention: 30 g/day of dark chocolate containing 500 mg total polyphenols and 100 mg vitamin E (n=25)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High polyphenol chocolate without additional vitamin E (n=25)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group maintaining baseline diet (n=25)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All groups will follow a similar physical exercise programme.
Number of subjects: 75
Study: 38135329

Group type: EXPERIMENTAL
Intervention: 8-week self-care intervention
Number of subjects: 25
Study: 38135333

Group type: EXPERIMENTAL
Intervention: in-hospital short-term PORT (education, inspiratory muscle training, active cycle of breathing techniques, early mobilisation)
Number of subjects: 800

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 800
Study: 38135359

Group type: EXPERIMENTAL
Intervention: HoloSNS for surgical planning using connectomic hypotheses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional neurosurgical planning workstations
Number of subjects: 0
Study: 38135369

Group type: EXPERIMENTAL
Intervention: HSCT (Hematopoietic Stem Cell Transplantation)
Number of subjects: 0
Study: 38135371

Group type: EXPERIMENTAL
Intervention: Oral decitabine-cedazuridine (35 mg decitabine and 100 mg cedazuridine once daily for 5 days)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Intravenous decitabine (20 mg/m2)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Oral decitabine-cedazuridine
Number of subjects: 133

Group type: COMPARATOR
Intervention: Intravenous decitabine
Number of subjects: 133
Study: 38135485

Group type: EXPERIMENTAL
Intervention: Pudexacianinium (ASP5354) 1.0 mg intravenous injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pudexacianinium (ASP5354) 3.0 mg intravenous injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pudexacianinium (ASP5354) 0.3 mg intravenous injection
Number of subjects: 0
Study: 38135494

Group type: EXPERIMENTAL
Intervention: Early and exclusive enteral nutrition (60-80 mL/kg/day within the first 36 hours after birth)
Number of subjects: 102
Study: 38135732

Group type: EXPERIMENTAL
Intervention: NIRF-C
Number of subjects: 338

Group type: COMPARATOR
Intervention: CVS-WL
Number of subjects: 338
Study: 38137083

Group type: EXPERIMENTAL
Intervention: Motor imagery training
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control condition (resting quietly)
Number of subjects: 56
Study: 38137533

Group type: EXPERIMENTAL
Intervention: Guideline-oriented therapy
Number of subjects: 0
Study: 38137669

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 35

Group type: COMPARATOR
Intervention: 6-Mercaptopurine (6-MP)
Number of subjects: 35
Study: 38140005

Group type: EXPERIMENTAL
Intervention: Ped-TMZ oral suspension
Number of subjects: 36

Group type: COMPARATOR
Intervention: TMZ capsules
Number of subjects: 36
Study: 38140184

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Baseline IgG levels ≥ 1.3 µg/mL
Number of subjects: 584

Group type: COMPARATOR
Intervention: Baseline IgG levels < 1.3 µg/mL
Number of subjects: 584
Study: 38140282

Group type: EXPERIMENTAL
Intervention: 4-month hypocaloric diet
Number of subjects: 0
Study: 38140802

Group type: EXPERIMENTAL
Intervention: Disability stage
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: History of arrhythmic disorder
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Risk score based on disability stage, arrhythmias, diabetes, and left ventricular systolic dysfunction
Number of subjects: 631
Study: 38140854

Group type: EXPERIMENTAL
Intervention: Intravenous belimumab 10 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 38141101

Group type: EXPERIMENTAL
Intervention: VLCHF diet
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: VLCHF + HIIT
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control
Number of subjects: 91
Study: 38141138

Group type: EXPERIMENTAL
Intervention: Iodine-containing multivitamin and mineral supplements (≥ 150 μg/day)
Number of subjects: 835

Group type: COMPARATOR
Intervention: Non-users of iodine-containing supplements
Number of subjects: 835
Study: 38141201

Group type: EXPERIMENTAL
Intervention: Higher physical activity at Month 6
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Higher physical activity at Month 6 (for patients with advanced cancer)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Sleep problems at baseline and Month 6
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Cross-lagged associations for sleep and fatigue
Number of subjects: 649
Study: 38141256

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 20 mg
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 70 mg
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200 mg
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 38141496

Group type: EXPERIMENTAL
Intervention: Sit-to-stand power (STS power)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Knee extensor maximal isometric strength (KE MVC)
Number of subjects: 86
Study: 38141595

Group type: EXPERIMENTAL
Intervention: Serum ischemia modified albumin (IMA), biglycan, and decorin levels
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combined model of IMA, decorin, and biglycan plus TVS CL measurement
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Prediction of preterm delivery
Number of subjects: 51
Study: 38141637

Group type: EXPERIMENTAL
Intervention: Doravirine (100 mg) continued
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Doravirine (100 mg) switched
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Doravirine (100 mg) continued or switched
Number of subjects: 1494
Study: 38141686

Group type: EXPERIMENTAL
Intervention: 19-gauge fine-needle biopsy (FNB) needle
Number of subjects: 42

Group type: COMPARATOR
Intervention: 22-gauge fine-needle biopsy (FNB) Franseen tip needle
Number of subjects: 42
Study: 38141723

Group type: EXPERIMENTAL
Intervention: Motorized FFR pullback pressure gradient (PPG) and wall shear stress (WSS) analyses
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Focal coronary artery disease (CAD) identified by high PPG
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Diffuse coronary artery disease (CAD)
Number of subjects: 105
Study: 38141721

Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma with 2 or more positive biomarkers
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma with 1 positive biomarker
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma with low blood EOS
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma triple-negative
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma overall
Number of subjects: 647

Group type: COMPARATOR
Intervention: Controlled asthma
Number of subjects: 647
Study: 38141879

Group type: EXPERIMENTAL
Intervention: Whole breast radiotherapy (WBRT) after breast conserving surgery with sentinel lymph node biopsy (SLNB)
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Whole breast radiotherapy (WBRT) after breast conserving surgery without sentinel lymph node biopsy (no-SLNB)
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Incidental axillary radiation therapy (RT) dose at axilla level I
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Tumour bed boost (yes)
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Tumour bed boost (no)
Number of subjects: 1461
Study: 38142026

Group type: EXPERIMENTAL
Intervention: Proprioceptive Training (PT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional Rehabilitation (CR)
Number of subjects: 30
Study: 38142044

Group type: EXPERIMENTAL
Intervention: Sildenafil (2 mg/kg/dose enterally every 12 hours for 7 days, 14 doses)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 24
Study: 38142046

Group type: EXPERIMENTAL
Intervention: Family-Based Treatment with Intensive Parental Coaching (IPC)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Family-Based Treatment (FBT)
Number of subjects: 107
Study: 38142263

Group type: EXPERIMENTAL
Intervention: Neural network (NN) algorithm for predicting appendicular lean mass (ALM)
Number of subjects: 576
Study: 38142448

Group type: EXPERIMENTAL
Intervention: Elevated white blood cell (WBC) count >11 × 10^9/L
Number of subjects: 2510

Group type: EXPERIMENTAL
Intervention: Hematocrit level >45%
Number of subjects: 2510

Group type: EXPERIMENTAL
Intervention: WBC count >12 × 10^9/L (when hematocrit controlled at ≤45%)
Number of subjects: 2510
Study: 38142605

Group type: EXPERIMENTAL
Intervention: Caffeine (n=26)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (n=27)
Number of subjects: 53
Study: 38142628

Group type: EXPERIMENTAL
Intervention: Pegvaliase
Number of subjects: 332

Group type: COMPARATOR
Intervention: Sapropterin + MNT
Number of subjects: 332

Group type: COMPARATOR
Intervention: MNT
Number of subjects: 332
Study: 38142639

Group type: EXPERIMENTAL
Intervention: Isoniazid exposure in plasma and CSF
Number of subjects: 48
Study: 38142660

Group type: EXPERIMENTAL
Intervention: Inline dynamometry
Number of subjects: 102
Study: 38142695

Group type: EXPERIMENTAL
Intervention: Leterovir (480 mg once daily, adjusted to 240 mg for participants on cyclosporin A) for 200 days
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo for 100 days
Number of subjects: 220
Study: 38142697

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Number of subjects: 731

Group type: COMPARATOR
Intervention: Standard optimal treatment alone (Control)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) for OSA
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) for CSA
Number of subjects: 731
Study: 38142702

Group type: EXPERIMENTAL
Intervention: dd-MVAC (every 2 weeks for a total of six cycles)
Number of subjects: 493

Group type: COMPARATOR
Intervention: GC (every 3 weeks for a total of four cycles)
Number of subjects: 493
Study: 38142801

Group type: EXPERIMENTAL
Intervention: Coalition members
Number of subjects: 1957

Group type: COMPARATOR
Intervention: Residents
Number of subjects: 1957
Study: 38142846

Group type: EXPERIMENTAL
Intervention: Mim8 (denecimig)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Emicizumab (exploratory cohort)
Number of subjects: 42
Study: 38142892

Group type: EXPERIMENTAL
Intervention: IV ketamine infusions (3 infusions over 11 days)
Number of subjects: 75
Study: 38143014

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Numeric Rating Scale (NRS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Comparison of VAS and NRS
Number of subjects: 39
Study: 38143022

Group type: EXPERIMENTAL
Intervention: YRI+ENTR
Number of subjects: 1151

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: ENTR
Number of subjects: 1151
Study: 38143352

Group type: EXPERIMENTAL
Intervention: Mexican American individuals
Number of subjects: 1901

Group type: COMPARATOR
Intervention: Non-Hispanic white individuals
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Educational attainment
Number of subjects: 1901